| Dr Sreekala P Satheesh, MD | |
|
20 Glenlake Parkway, Kaiser Permanente Glenlake Medical Center, Atlanta, GA 30328 | |
| (770) 677-6247 | |
| (404) 252-5839 |
| Full Name | Dr Sreekala P Satheesh |
|---|---|
| Gender | Female |
| Speciality | Gastroenterology |
| Experience | 28 Years |
| Location | 20 Glenlake Parkway, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881885911 | NPI | - | NPPES |
| CB5609 | Other | GA | RAILROAD MEDICARE |
| GRP1077 | Other | GA | MEDICARE GROUP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 062602 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Joseph's Hospital Of Atlanta, Inc | Atlanta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Southeast Permanente Medical Group | 6204829013 | 576 |
News Archive
A new study offered at Houston Methodist Hospital will compare an emerging immunotherapy drug to an existing chemotherapy drug and look at the effects both drugs have on the development of non-small cell lung cancer, a type of cancer which makes up about 85 percent of lung cancer cases.
Three surgeons will showcase implant technology from global engineering and healthcare technologies company, Renishaw, during a masterclass at the British Association of Oral and Maxillofacial Surgeons conference this year.
Santarus, Inc., a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with either the investigational drug budesonide MMX 6 mg or placebo will be provided as support for the company's planned submission of a New Drug Application (NDA) for budesonide MMX 9 mg to the U.S. Food and Drug Administration (FDA) for the induction of remission of mild or moderate active ulcerative colitis.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
› Verified 1 days ago
| Entity Name | The Southeast Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245266956 PECOS PAC ID: 6204829013 Enrollment ID: O20040407000370 |
News Archive
A new study offered at Houston Methodist Hospital will compare an emerging immunotherapy drug to an existing chemotherapy drug and look at the effects both drugs have on the development of non-small cell lung cancer, a type of cancer which makes up about 85 percent of lung cancer cases.
Three surgeons will showcase implant technology from global engineering and healthcare technologies company, Renishaw, during a masterclass at the British Association of Oral and Maxillofacial Surgeons conference this year.
Santarus, Inc., a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with either the investigational drug budesonide MMX 6 mg or placebo will be provided as support for the company's planned submission of a New Drug Application (NDA) for budesonide MMX 9 mg to the U.S. Food and Drug Administration (FDA) for the induction of remission of mild or moderate active ulcerative colitis.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sreekala P Satheesh, MD 3495 Piedmont Road, Nine Piedmont Center, Atlanta, GA 30305 Ph: (404) 252-9307 | Dr Sreekala P Satheesh, MD 20 Glenlake Parkway, Kaiser Permanente Glenlake Medical Center, Atlanta, GA 30328 Ph: (770) 677-6247 |
News Archive
A new study offered at Houston Methodist Hospital will compare an emerging immunotherapy drug to an existing chemotherapy drug and look at the effects both drugs have on the development of non-small cell lung cancer, a type of cancer which makes up about 85 percent of lung cancer cases.
Three surgeons will showcase implant technology from global engineering and healthcare technologies company, Renishaw, during a masterclass at the British Association of Oral and Maxillofacial Surgeons conference this year.
Santarus, Inc., a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with either the investigational drug budesonide MMX 6 mg or placebo will be provided as support for the company's planned submission of a New Drug Application (NDA) for budesonide MMX 9 mg to the U.S. Food and Drug Administration (FDA) for the induction of remission of mild or moderate active ulcerative colitis.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
› Verified 1 days ago
Khadeja Jamilia Johnson, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1800 Howell Mill Rd Nw Ste 275, Atlanta, GA 30318 Phone: 404-756-1290 | |
Dr. Matthew J. Wilson, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 755 Mt Vernon Hwy, Suite 530, Atlanta, GA 30328 Phone: 404-252-7970 Fax: 404-250-0553 | |
Kajal Patel, M.D, M.P.H Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1525 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-778-2700 | |
Dr. Earl Stewart Jr., M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2850 Paces Ferry Rd Se Ste 460, Atlanta, GA 30339 Phone: 678-556-4950 | |
Mary E. Bergh, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 980 Johnson Ferry Rd Ste 520, Atlanta, GA 30342 Phone: 404-303-3320 Fax: 404-303-3464 | |
John J Doran, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1365 Clifton Rd Ne Bldg A, The Emory Clinic - Nephrology, Atlanta, GA 30322 Phone: 404-778-5380 | |
Frank A Anania, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1365 Clifton Rd Ne Ste B1266, The Emory Clinic - Gastroenterology, Atlanta, GA 30322 Phone: 404-778-3184 |